Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Two-part Multicenter Study: a Randomized, Double-blind, Placebo-controlled Dose-escalation Safety Phase (Part 1) Followed by Double-blind, Placebo-controlled, Adaptive Phase (Part 2) Study to Evaluate the Safety and Efficacy of AB-1003 in Adult Subjects With LGMD2I/R9 Mutations in the Gene Encoding Fukutin Related Protein (FKRP)

NCT05230459 is registered in ClinicalTrials.gov with AskBio Inc as lead sponsor.

NCT NCT05230459
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05230459 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Two-part Multicenter Study: a Randomized, Double-blind, Placebo-controlled Dose-escalation Safety Phase (Part 1) Followed by Double-blind, Placebo-controlled, Adaptive Phase (Part 2) Study to Evaluate the Safety and Efficacy of AB-1003 in Adult Subjects With LGMD2I/R9 Mutations in the Gene Encoding Fukutin Related Protein (FKRP)
Lead sponsor
AskBio Inc
Phase
Phase 1/2
Overall status
Active, not recruiting
Start date
May 15, 2023
Completion date
December 31, 2032
Enrollment
9 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

fkrp, fkrp mutation, fukutin related protein, lgmd, lgmd2, lgmd2i, limb girdle muscular dystrophy, limb-girdle muscular dystrophy type 2, muscular dystrophy